Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy.
Wenzheng XiongTianrong YeoJeanne Tan May MayTor DemmersBryan CeronieArchana RameshRonan N McGintySophia MichaelEmma TorzilloArjune SenDaniel C AnthonySarosh R IraniFay ProbertPublished in: Annals of clinical and translational neurology (2024)
This study presents the first non-antibody-based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- genome wide
- mass spectrometry
- multiple sclerosis
- small molecule
- blood glucose
- type diabetes
- dna methylation
- magnetic resonance imaging
- gene expression
- drug induced
- cerebral ischemia
- risk assessment
- magnetic resonance
- subarachnoid hemorrhage
- blood brain barrier